hero image

Biogen Idec to Present at the Credit Suisse 2012 Annual Healthcare Conference

November 7, 2012 News Release

WESTON, Mass.--(BUSINESS WIRE)--Biogen Idec Inc. (NASDAQ: BIIB) announced today that its presentation at the Credit Suisse 2012 Healthcare Conference will be webcast live on Wednesday, November 14, 2012 at 9:30 a.m. MT, 7:30am ET. To access the live webcast, please visit Biogen Idec’s Investors section at www.biogenidec.com. An archived version of the webcast will be available for 14 days following the presentation.

About Biogen Idec

Through cutting-edge science and medicine, Biogen Idec discovers, develops and delivers to patients worldwide innovative therapies for the treatment of neurodegenerative diseases, hemophilia and autoimmune disorders. Founded in 1978, Biogen Idec is the world’s oldest independent biotechnology company. Patients worldwide benefit from its leading multiple sclerosis therapies, and the company generates more than $5 billion in annual revenues. For product labeling, press releases and additional information about the company, please visit www.biogenidec.com.

 

Contact:

Biogen Idec
Karen Jewell, 781-464-2442
Investor Relations

thumb
February 6, 2023
Biogen and Sage Therapeutics Announce FDA Accepts Filing of New Drug Application and Grants Priority Review of Zuranolone in the Treatment of Major Depressive Disorder and Postpartum Depression

Zuranolone is being evaluated as a potential 14-day, rapid-acting, once-daily, oral medication to treat major depressive disorder (MDD) and postpartum depression (PPD) Depression is a public health issue with significant unmet medical need CAMBRIDGE, Mass., Feb.

thumb
January 29, 2023
Lecanemab Receives Priority Review Status in Japan

TOKYO and CAMBRIDGE, Mass., Jan. 29, 2023 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, "Biogen") announced today that an application for